Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objective: The aim of this case-control study was to assess the efficacy of dapagliflozin combined with metformin for type-2 diabetes mellitus (T2DM) with obstructive sleep apnea hypopnea syndrome (OSAHS). Methods: A total of 36 patients with newly-diagnosed T2DM and OSAHS were randomized divided into two groups. Eighteen OSAHS patients with T2DM, who were treated with dapagliflozin and metformin, were assigned as the dapagliflozin group. These patients were given dapagliflozin and metformin for 24 weeks between February 2017 and February 2018. Another 18 OSAHS patients with T2DM, who were treated with glimepiride and metformin for 24 weeks, were assigned as the control group. Fasting plasma glucose (FPG) level, postprandial blood glucose (PPG), hemoglobin A1C (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), blood lipids, body mass index (BMI), blood pressure, apnea-hypopnea index (AHI), minimum oxygen saturation (LSpO 2), and Epworth Somnolence Scale (ESS) score were measured before and at 24 weeks after the initiation of treatment. Results: In the dapagliflozin group, triglyceride (TG), systolic pressure (SBP) and diastolic pressure (DBP) significantly decreased following treatment, while high-density lipoprotein cholesterol (HDL-C) significantly increased (P < 0.05). Furthermore, a reduction in AHI, an increase in LSpO 2 and a decrease in ESS score were observed in the dapagliflozin group (P < 0.05), but not in the control group. Moreover, blood glucose, HbA1c, HOMA-IR, and BMI significantly decreased in these two groups, and the decrease was more significant in the dapagliflozin group. Conclusion: These present results indicate that dapagliflozin can significantly reduce glucose, BMI, blood pressure and AHI, and improve hypoxemia during sleep and excessive daytime sleepiness, which thereby has potential as an effective treatment approach for OSAHS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes
Foster, G. D., Sanders, M. H., Millman, R., Zammit, G., Borradaile, K. E., Newman, A. B., Wadden, T. A., Kelley, D., Wing, R. R., Pi Sunyer, F. X., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1776 · Cited by 600
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Non-CPAP therapies in obstructive sleep apnoea
Randerath, W. J., Verbraecken, J., Andreas, S., Bettega, G., Boudewyns, A., Hamans, E., Jalbert, F., Paoli, J. R., Sanner, B., Smith, I., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00099710 · Cited by 388
Gaddam, K., Pimenta, E., Thomas, S. J., Cofield, S. S., Oparil, S., Harding, S. M., & Calhoun, D. A. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2009.96 · Cited by 289
Effects of metformin on weight loss: potential mechanisms
Malin, S. K., & Kashyap, S. R. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000095 · Cited by 223
Obesity and obstructive sleep apnea – Clinical significance of weight loss
Tuomilehto, H., Seppä, J., & Uusitupa, M. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2012.08.002 · Cited by 215
Sleep Apnea and Cardiovascular Disease: An Enigmatic Risk Factor
Floras, J. S. (2018) · Circulation Research · doi:10.1161/circresaha.118.310783 · Cited by 209
Kasai, T., Bradley, T. D., Friedman, O., & Logan, A. G. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000047 · Cited by 127
Cited by
Schipper, S. B. J., Van Veen, M. M., Elders, P. J. M., van Straten, A., Van Der Werf, Y. D., Knutson, K. L., & Rutters, F. (2021) · Diabetologia · doi:10.1007/s00125-021-05541-0 · Cited by 202
“One study examined the effect of type 2 diabetes medication associated with weight loss on OSA in type 2 diabetes [62].”
BackgroundNew frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review
Schütz, S. G., Dunn, A., Braley, T. J., Pitt, B., & Shelgikar, A. V. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101473 · Cited by 47
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
Wojeck, B. S., Inzucchi, S. E., Neeland, I. J., Mancuso, J. P., Frederich, R., Masiukiewicz, U., Cater, N. B., McGuire, D. K., Cannon, C. P., & Yaggi, H. K. (2023) · Sleep and Breathing · doi:10.1007/s11325-022-02594-2 · Cited by 41
Metadata
- Authors
- Tang, Y., Sun, Q., Bai, X.-Y., Zhou, Y.-F., Zhou, Q.-L., & Zhang, M.
- Venue
- Nutrition & Diabetes
- Published
- 2019-11-04
- Volume
- 9
- Issue
- 1
- Pages
- 32-32
- ISSN
- 2044-4052 (ISSN-L)
- OpenAlex
- W2985327520
- Cited by
- 73
- References
- 11
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. https://app.cochat.ai/papers/10.1038/s41387-019-0098-5
- The paper
- Tang, Y., Sun, Q., Bai, X.-Y., Zhou, Y.-F., Zhou, Q.-L., & Zhang, M. (2019). Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. Nutrition & Diabetes. https://doi.org/10.1038/s41387-019-0098-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.